Trial · NCT02187159
Results by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 112
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | -1.86 | Standard Error 0.130 | units on a scale | |
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | -2.47 | Standard Error 0.133 | units on a scale | |
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | -2.24 | Standard Error 0.133 | units on a scale | |
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | -2.09 | Standard Error 0.134 | units on a scale | |
| Number of Participants Who Answered Much Improved or Better on the Patient Global Impression of Change (PGIC) Scale at Week 13 in Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | 91 | Participants | ||
| Number of Participants Who Answered Much Improved or Better on the Patient Global Impression of Change (PGIC) Scale at Week 13 in Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | 141 | Participants | ||
| Number of Participants Who Answered Much Improved or Better on the Patient Global Impression of Change (PGIC) Scale at Week 13 in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | 116 | Participants | ||
| Number of Participants Who Answered Much Improved or Better on the Patient Global Impression of Change (PGIC) Scale at Week 13 in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | 117 | Participants | ||
| Change From Baseline to Week 13 in Fibromyalgia Index Questionnaire (FIQ) Total Score in Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | -13.88 | Standard Deviation 1.20 | units on a scale | |
| Change From Baseline to Week 13 in Fibromyalgia Index Questionnaire (FIQ) Total Score in Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | -21.46 | Standard Deviation 1.22 | units on a scale | |
| Change From Baseline to Week 13 in Fibromyalgia Index Questionnaire (FIQ) Total Score in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | -17.41 | Standard Deviation 1.22 | units on a scale | |
| Change From Baseline to Week 13 in Fibromyalgia Index Questionnaire (FIQ) Total Score in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | -16.45 | Standard Deviation 1.24 | units on a scale | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | 30% Responders | 113 | Participants | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | 30% Responders | 139 | Participants | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | 30% Responders | 123 | Participants | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | 30% Responders | 118 | Participants | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | 50% Responders | 61 | Participants | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | 50% Responders | 90 | Participants | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | 50% Responders | 79 | Participants | |
| Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | 50% Responders | 68 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02187159/results